Comparative Efficacy of Azithromycin and Clarithromycin in the Management of Helicobacter pylori Infection

Sami H Alhijazien; Shadi Daoud; Marwan T Alzayadi; Majd R Al Sarhan; Moayad K Aldomi; Talal A Al Shawabkeh; Mohammad  M Alsmadi

doi:10.7759/cureus.72033

journal article Oct 21, 2024

Comparative Efficacy of Azithromycin and Clarithromycin in the Management of Helicobacter pylori Infection

Sami H Alhijazien Shadi Daoud Marwan T Alzayadi Majd R Al Sarhan Moayad K Aldomi Talal A Al Shawabkeh Mohammad M Alsmadi

Cureus · Springer Science and Business Media LLC

View at Publisher Save 10.7759/cureus.72033

Topics

No keywords indexed for this article. Browse by subject →

References

25

[1]

González-Stegmaier R, Aguila-Torres P, Villarroel-Espíndola F. Historical and molecular perspectives on the presence of Helicobacter pylori in Latin America: a niche to improve gastric cancer risk assessment. Int J Mol Sci. 2024, 25:1761. 10.3390/ijms25031761 10.3390/ijms25031761

[2]

González Segovia R, Romo Lozano Y, Rodríguez MG, Montañez Flores AL, González Macías J. Identification of serologically active Helicobacter pylori antigens related to alterations in serum pepsinogen levels. Rev Argent Microbiol. 2023, 55:355-65. 10.1016/j.ram.2023.04.003 10.1016/j.ram.2023.04.003

[3]

Malfertheiner P, Megraud F, Rokkas T, et al.. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022, 10.1136/gutjnl-2022-327745 10.1136/gutjnl-2022-327745

[4]

De Francesco V, Zullo A, Manta R, et al.. Culture-based antibiotic susceptibility testing for Helicobacter pylori infection: a systematic review. Ann Gastroenterol. 2022 Mar, 35:127-34. 10.20524%2Faog.2022.0689 10.20524%2faog.2022.0689

[5]

Ding YM, Li YY, Liu J, et al.. The cure rate of 10-day bismuth-containing quadruple therapy for Helicobacter pylori eradication is equivalent to 14-day: a systematic review and meta-analysis. Clin Exp Med. 2023, 23:1033-43. 10.1007/s10238-022-00953-7 10.1007/s10238-022-00953-7

[6]

Yin Z, Li J, Huang W, et al.. High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis. Turk J Gastroenterol. 2022, 33:454-62. 10.5152/tjg.2022.21579 10.5152/tjg.2022.21579

[7]

Roszczenko-Jasińska P, Wojtyś MI, Jagusztyn-Krynicka EK. Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets. Appl Microbiol Biotechnol. 2020, 104:9891-905. 10.1007/s00253-020-10945-w 10.1007/s00253-020-10945-w

[8]

Gupta A, Shetty S, Mutalik S, et al.. Treatment of H. pylori infection and gastric ulcer: need for novel pharmaceutical formulation. Heliyon. 2023, 9:e20406. 10.1016/j.heliyon.2023.e20406 10.1016/j.heliyon.2023.e20406

[9]

Mahgoub SM, Shehata MR, Zaher A, Abo El-Ela FI, Farghali A, Amin RM, Mahmoud R. Cellulose-based activated carbon/layered double hydroxide for efficient removal of Clarithromycin residues and efficient role in the treatment of stomach ulcers and acidity problems. Int J Biol Macromol. 2022, 215:705-28. 10.1016/j.ijbiomac.2022.06.136 10.1016/j.ijbiomac.2022.06.136

[10]

Murata M, Sugimoto M, Mizuno H, Kanno T, Satoh K. Clarithromycin versus metronidazole in first-line Helicobacter pylori triple eradication therapy based on resistance to antimicrobial agents: meta-analysis. J Clin Med. 2020, 9:543. 10.3390/jcm9020543 10.3390/jcm9020543

[11]

Jha SK, Kumar R, Kumar A, Purkayastha S, Keshri R, Kumar S, Singh AV. Addition of nitazoxanide to standard clarithromycin based triple therapy for 2 weeks effectively eradicates treatment-naive Helicobacter pylori infection. A single centre prospective, open-label study. Middle East J Dig Dis. 2022, 14:77-84. 10.34172/mejdd.2022.259 10.34172/mejdd.2022.259

[12]

Kang S, Kim Y, Ahn JY, et al.. Role of antimicrobial susceptibility testing before first-line treatment containing clarithromycin for Helicobacter pylori eradication in the clinical setting. Antibiotics (Basel). 2021, 10:10.3390/antibiotics10020214 10.3390/antibiotics10020214

[13]

Shah SC, Tepler A, Chung CP, et al.. Host genetic determinants associated with Helicobacter pylori eradication treatment failure: a systematic review and meta-analysis. Gastroenterology. 2021, 161:1443-59. 10.1053/j.gastro.2021.07.043 10.1053/j.gastro.2021.07.043

[14]

Riley RD, Van Calster B, Collins GS. A note on estimating the Cox-Snell R(2) from a reported C statistic (AUROC) to inform sample size calculations for developing a prediction model with a binary outcome. Stat Med. 2021, 40:859-64. 10.1002/sim.8806 10.1002/sim.8806

[15]

Jung HK, Kang SJ, Lee YC, et al.. Evidence-based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. Gut Liver. 2021, 15:168-95. 10.5009/gnl20288 10.5009/gnl20288

[16]

Daver NG, Dail M, Garcia JS, et al.. Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial. Blood. 2023, 141:1265-76. 10.1182/blood.2022016362 10.1182/blood.2022016362

[17]

Berežni S, Mimica-Dukić N, Domina G, Raimondo FM, Orčić D. Anthriscus sylvestris-noxious weed or sustainable source of bioactive lignans?. Plants (Basel). 2024, 13:1087. 10.3390/plants13081087 10.3390/plants13081087

[18]

Shah S, Hubscher E, Pelletier C, Jacob R, Vinals L, Yadlapati R. Helicobacter pylori infection treatment in the United States: clinical consequences and costs of eradication treatment failure. Expert Rev Gastroenterol Hepatol. 2022, 16:341-57. 10.1080/17474124.2022.2056015 10.1080/17474124.2022.2056015

[19]

Huang TH, Yang SC, Tai WC, et al.. The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance. Biomed J. 2021, 44:S275-81. 10.1016/j.bj.2020.11.012 10.1016/j.bj.2020.11.012

[20]

Liu C, Wang Y, Shi J, Zhang C, Nie J, Li S, Zheng T. The status and progress of first-line treatment against Helicobacter pylori infection: a review. Therap Adv Gastroenterol. 2021, 14:10.1177/1756284821989177 10.1177/1756284821989177

[21]

Tauqeer M, Talpur MT, Ahmed T, Aamer N, Shabir S, Yaqoob U . Efficacy of triple regimen therapy for H. pylori eradication with and without azithromycin. Pak J Surg. 2020, 36:152-6.

[22]

Kwon YM, Kim SJ, Lee JG, Lee SP. Effects of prior antibiotic use on clarithromycin resistance in Helicobacter pylori. Helicobacter. 2023, 28:e12974. 10.1111/hel.12974 10.1111/hel.12974

[23]

Roberts LT, Issa PP, Sinnathamby ES, et al.. Helicobacter pylori: a review of current treatment options in clinical practice. Life (Basel). 2022, 12:2038. 10.3390/life12122038 10.3390/life12122038

[24]

Metwally M, Ragab R, Abdel Hamid HS, Emara N, Elkholy H. Helicobacter pylori antibiotic resistance in Egypt: a single-center study. Infect Drug Resist. 2022, 15:5905-13. 10.2147/IDR.S386082 10.2147/idr.s386082

[25]

Bujanda L, Nyssen OP, Vaira D, et al.. Antibiotic resistance prevalence and trends in patients infected with Helicobacter pylori in the period 2013-2020: Results of the European Registry on H. pylori Management (Hp-EuReg). Antibiotics (Basel). 2021, 10:1058. 10.3390/antibiotics10091058 10.3390/antibiotics10091058

Metrics

1

Citations

25

References

Details

Published: Oct 21, 2024

Authors

Cite This Article

Sami H Alhijazien, Shadi Daoud, Marwan T Alzayadi, et al. (2024). Comparative Efficacy of Azithromycin and Clarithromycin in the Management of Helicobacter pylori Infection. Cureus. https://doi.org/10.7759/cureus.72033

Comparative Efficacy of Azithromycin and Clarithromycin in the Management of Helicobacter pylori Infection

You May Also Like